Table 7. Hazard ratios of various end... | American Society of Hematology

Table 7.

Hazard ratios of various end points calculated by means of competing-risk regression

End point and variable	No.patients	No.events	Hazard ratio (95% CI)	P
BMF
Group
A/G	253	213	1.0^7-151	NA
C	78	73	1.5 (1.1-2.0)	.005
Nontyped^7-150	413	307	0.75 (0.63-0.89)	.001
FANCC mutations
Exon 1	27	25	1.0^7-151	NA
Intron 4/exon 14	50	47	3.8 (2.1-6.9)	< .0001
Hematologic malignancy
Sex
Female	367	49	1.0^7-151	NA
Male	387	71	1.5 (1.1-2.2)	.02
Solid tumor
Sex
Female	367	48	1.0^7-151	NA
Male	387	25	0.52 (0.33-0.83)	.007
SCC
Sex
Female	349	30	1.0^7-151	NA
Male	371	9	0.30 (0.15-0.61)	.001

End point and variable	No.patients	No.events	Hazard ratio (95% CI)	P
BMF
Group
A/G	253	213	1.0^7-151	NA
C	78	73	1.5 (1.1-2.0)	.005
Nontyped^7-150	413	307	0.75 (0.63-0.89)	.001
FANCC mutations
Exon 1	27	25	1.0^7-151	NA
Intron 4/exon 14	50	47	3.8 (2.1-6.9)	< .0001
Hematologic malignancy
Sex
Female	367	49	1.0^7-151	NA
Male	387	71	1.5 (1.1-2.2)	.02
Solid tumor
Sex
Female	367	48	1.0^7-151	NA
Male	387	25	0.52 (0.33-0.83)	.007
SCC
Sex
Female	349	30	1.0^7-151	NA
Male	371	9	0.30 (0.15-0.61)	.001

NA indicates not applicable.

Complementation group unknown.

Baseline.